ESCaPE-CMD (CLBS14-CMD)

Study Information

ESCaPE-CMD is a Phase 2 study evaluating an autologous CD34 cell therapy (CLBS14-CMD) for the treatment of coronary microvascular dysfunction (CMD) at two centers in the United States. For more information on this study, please visit www.escapecmd.com.
Status: Active - Enrolling